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BACKGROUND: People with colorectal cancer have impaired quality of life (QoL). We investigated what factors were most highly
associated with it.
METHODS: Four hundred and ninety-six people with colorectal cancer completed questionnaires about QoL, functioning, symptoms,
co-morbidity, cognitions and personal and social factors. Disease, treatment and co-morbidity data were abstracted from case notes.
Multiple linear regression identified modifiable and unmodifiable factors independently predictive of global quality of life (EORTC-
QLQ-C30).
RESULTS: Of unmodifiable factors, female sex (Po0.001), more self-reported co-morbidities (P¼0.006) and metastases at diagnosis
(P¼0.036) significantly predicted poorer QoL, but explained little of the variability in the model (R
2¼0.064). Adding modifiable
factors, poorer role (Po0.001) and social functioning (P¼0.003), fatigue (P¼0.001), dyspnoea (P¼0.001), anorexia (Po0.001),
depression (Po0.001) and worse perceived consequences (P¼0.013) improved the model fit considerably (R
2¼0.574). Omitting
functioning subscales resulted in recent diagnosis (P¼0.002), lower perceived personal control (P¼0.020) and travel difficulties
(Po0.001) becoming significant predictors.
CONCLUSION: Most factors affecting QoL are modifiable, especially symptoms (fatigue, anorexia, dyspnoea) and depression. Beliefs
about illness are also important. Unmodifiable factors, including metastatic (or unstaged) disease at diagnosis, have less impact. There
appears to be potential for interventions to improve QoL in patients with colorectal cancer.
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Colorectal cancer is the third most common cancer in the UK and,
with advances in treatment, more people are not only being cured,
but also surviving for longer with the disease (http://info.cancer
researchuk.org/cancerstats/incidence/commoncancers/). Treatment
almost always involves surgery, can result in stomas and is
frequently accompanied by chemotherapy, radiotherapy or both
(SIGN, 2003). The adverse effects of both the disease and its
treatment can be longstanding, including lack of energy, bowel
problems, poor body image and emotional problems (Phipps et al,
2008), as well as sleep difficulties, fear of recurrence, anxiety,
depression, sensory neuropathy, gastrointestinal problems, urinary
incontinence and sexual dysfunction (Denlinger and Barsevick,
2009). Moreover, most people with colorectal cancer are older and
may have functional limitations, geriatric syndromes and other
significant conditions (including heart disease, chronic obstructive
pulmonary disease and other cancers) that are likely to affect how
they feel (Koroukian et al, 2010). Improving their quality of life
(QoL) will, then, be complex, having to take account of multiple
factors related to the cancer, its treatment, other conditions, social
factors and the person’s response. To tackle this challenge, we need
first to identify the potentially modifiable and fixed factors most
associated with better or worse QoL.
Previous research has helped to highlight some factors associated
with poorer QoL in colorectal cancer (Steginga et al, 2009). People
with more advanced disease (Sharma et al, 2007), women (Pucciarelli
et al, 2008) and those with certain symptoms, especially diarrhoea
and constipation (Wilson et al, 2006), report poorer QoL. However,
much evidence is conflicting or inconclusive – for example, stomas
may or may not be detrimental to QoL (Wilson et al, 2006; Cornish
et al, 2007; Ross et al, 2007; Wilson and Alexander, 2008; Bloemen
et al, 2009; Krouse et al, 2009; Yau et al, 2009), older people may have
better or worse QoL than younger people (Pucciarelli et al, 2008;
Wilson and Alexander, 2008) and there are suggestions that non-
disease factors may be more important than disease factors (Siassi
et al, 2009).
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sThis study was conducted to inform attempts to improve the
QoL of people with colorectal cancer. It was undertaken as part of
a programme of work to establish the potential for primary care to
tackle social inequalities for people with colorectal cancer. The
aims were to (1) quantify the health-related quality of life
(HRQOL) in people with a confirmed diagnosis of colorectal
cancer and (2) identify both modifiable and unmodifiable (or
fixed) factors associated with poorer HRQOL.
MATERIALS AND METHODS
Participants
Participants recently diagnosed with colorectal cancer were
recruited in North East Scotland, via the colorectal cancer
multidisciplinary team, and in Glasgow, via the colorectal
specialist nurses. In addition, participants 1–2 years into follow
up were recruited in North East Scotland via colorectal oncology
and surgical outpatient clinics. Participants were eligible for
inclusion in the study if they had had a definitive diagnosis of
colorectal cancer, and had commenced their initial treatment
(normally surgery or, in non-resectable cases, palliative radio-
therapy or chemotherapy). Participants were excluded from the
study if they were unable to give informed consent or complete the
questionnaire (e.g., due to dementia), or, in the opinion of their
clinical team, had a life expectancy of o1 month.
Eligible participants were initially approached by a member of
the clinical team treating them. Willing participants were then
contacted by the researchers who sought written informed consent
for participation. Participants were asked to complete a ques-
tionnaire booklet (see below). Most questionnaires were completed
during face-to-face interviews with one of the research team.
However, some participants, who stated a preference or lived long
distances away (e.g., in Orkney or Shetland), self-completed the
questionnaires or were interviewed by telephone.
This project was reviewed and fully approved by the Multi-
Centre Research Ethics Committee for Scotland, Committee A.
Materials
The main outcome variable was global HRQOL, measured using
the EORTC-QLQ-C30 (http://www.eortc.be/home/qol/). This is a
validated and widely used instrument to measure overall HRQOL
in people with cancer. The QLQ-C30 comprises five functional
scales (physical, role, cognitive, emotional and social), three
symptom scales (fatigue, pain and nausea and vomiting), and a
number of single items assessing additional symptoms commonly
reported by people with cancer (dyspnoea, loss of appetite,
insomnia, constipation and diarrhoea) and perceived financial
impact of the disease. These additional scales/items were included
in the analysis as independent variables.
Other independent variables for inclusion in the analysis were
collected by questionnaire and abstraction from case notes. The
Hospital Anxiety and Depression scale (HADS) (Zigmond and
Snaith, 1983) was used to measure participant levels of anxiety and
depression. The revised Illness Perception Questionnaire (IPQ-R)
was used to assess six components of illness representation in
Leventhal’s common sense self-regulation model, which has been
previously found to predict coping, health seeking behaviour,
adherence to treatment, mood and functional adaptation (Moss-
Morris et al, 2002; Hagger and Orbell, 2003). The Social Difficulties
Inventory (SDI) was used to identify individuals with social
problems (Wright et al, 2007).
The personal and social data collected included date of birth,
postcode, living arrangements (i.e., living on own, living with
spouse, living with others), dependents, ethnicity, education,
employment status, home ownership and annual income. A small
area-based measure of deprivation (Carstairs quintile grouping)
was assigned to participants according to postcode of residence.
The urban/rural status of the participant’s postcode was allocated
using the 2005–2006 Scottish Executive Urban Rural 6-category
Classification (http://www.scotland.gov.uk/Publications/2006/07/
31114822/UR2006downloads), participants were defined as living
in an accessible or remote area. Participants’ travelling time from
home to nearest cancer centre was calculated using a cutoff of
60min travelling time to categorise participants.
Participants were also asked about their health and any illnesses
they may have had. This included questions related to
co-morbidities, smoking habits and current pain/discomfort.
Participant-reported (PR) co-morbidities were included in the
analyses firstly, as a count of the number of co-morbidities, and
secondly, for more common diseases (with prevalence X10%) as
an individual co-morbidity. To complement information from
questionnaires, data were also collected from general practice (GP)
and hospital case notes on disease stage, treatments undertaken
and co-morbidities.
Time from date of diagnosis to completion of the questionnaire
was used to categorise participants into either (1) ‘newly
diagnosed’ (questionnaire completed up to 26 weeks from date
of diagnosis) or (2) ‘follow up’ (questionnaire completed 48 weeks
or more from date of diagnosis). Fifteen participants falling
outside these time frames were ineligible for the study and were
coded as missing.
Statistical methods
Descriptive statistics and histograms were produced for each
of the outcome measures. The distribution of each scale was
checked for normality and descriptive statistics were examined
to check for skewness. The HADS scores were categorised into case
or non-case using a cutoff score of 8 or more to determine
caseness for each of anxiety and depression (Bjelland et al, 2002).
In order to facilitate interpretation, the subscale scores of the QLQ-
C30 and the IPQ-R were split into tertiles. An SDI summary score
was calculated using 16 items from the scale and dichotomised
using a score below 10 to indicate ‘no difficulties’ and a score
of 10 or more to indicate ‘some difficulties’. The remaining five
SDI scale items were dichotomised into ‘no difficulties’ and ‘some
difficulties’.
The independent samples t-test and analysis of variance were
used to test whether there were significant differences in the mean
QoL scores across five groups of variables: (1) personal and social
factors, (2) disease and treatment factors, (3) PR co-morbidities,
(4) hospital and GP case note reported co-morbidities and (5)
questionnaire responses, including QLQ-C30 function and
symptom scales, social difficulties, illness perceptions and anxiety
and depression. Variables with a P-value of 0.1 or less were
included in multiple linear regression models to identify (for each
of the five groupings) which factors were predictive of QoL score.
Variables with a P-value of 0.1 or less from each of the
multi-adjusted models were then included in a final multiple
linear backward stepwise regression model to identify which
factors remained independently predictive of QoL score. The final
model was rerun on the full data set, entering first fixed variables
and then modifiable ones to provide data on how much variability
was explained by each.
The functioning subscales of the QLQ-C30 include questions
about activity limitations and participation restrictions. These
factors may to some extent mediate the effects of other factors on
QoL, so the regression modelling was repeated omitting these
scales to determine what effect that would have (if any) on the
predictors of QoL score.
Throughout all statistical analyses, a two-sided P-value p0.05
was used as the threshold for statistical significance.
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sRESULTS
A total of 496 participants are included in the analysis, 187 from
Glasgow and 309 from North East Scotland (including the islands
of Orkney and Shetland). One person was excluded due to
incomplete questionnaire data. The mean age of participants was
66 (s.d., 11.11 years); over 70% of participants were over the age of
60. Descriptive statistics for all of the variables considered in the
analyses are provided in Supplementary Tables 1–5.
In Glasgow, participants were identified by five clinical staff
members in three hospitals; clinical staff did not retain details of
who had been approached; thus, it was not possible to calculate
recruitment or consenting rates. In Grampian, recruitment was
from four hospitals; eligible participants were identified by
researchers and then approached by a member of the clinical
team. Of 436 eligible patients, 310 (71%) were recruited (Figure 1).
The mean QoL score was 65.791 (s.d., 21.81).
Personal and social factors (R
2¼0.068)
When the personal and social factors with a P-value of 0.1 or less
in univariate analyses were modelled together sex, income, urban
rural status and home ownership remained independently
predictive of QoL score (Table 1). Thus, those with the lowest
QoL scores were women, those who had lower incomes, lived in
accessible areas and did not own their own home.
Disease and treatment factors (R
2¼0.090)
Disease stage was categorised initially as (1) complete response to
neoadjuvant chemo-radiotherapy before pathological staging
(n¼13), (2) Dukes A (n¼67), (3) Dukes B (n¼171), (4) Dukes C
(n¼151), (5) metastatic (n¼71) or (6) unstaged (n¼23). Initial
univariate analyses showed few differences in QoL among partici-
pants with a complete response and those diagnosed with Dukes A
through C. Participants with metastatic or unstaged disease at
diagnosis had the poorest QoL. For the remaining analyses, staging
was collapsed into two categories: (1) complete response through to
Dukes C and (2) metastatic and unstaged. Shorter time since
diagnosis was significantly associated with poorer QoL, but
recurrence was not. Of the treatments received, surgery and palliative
Table 1 Associations between QLQ-C30 global quality of life score and personal and social factors, disease and treatment factors, PR co-morbidities
and hospital and GP case note reported co-morbidities
Univariate analysis Multivariate analysis
B s.e. P-value B s.e. P-value
Personal and social factors (multi-adjusted R
2¼0.068)
a
Sex  7.180 1.945 o0.001  5.255 2.197 0.017
Income 3.209 0.783 o0.001 2.201 0.838 0.009
Carstairs quintiles  1.704 0.658 0.010
Urban rural status 4.111 2.180 0.060 4.249 2.330 0.069
Home ownership  9.186 2.388 o0.001  6.719 2.860 0.019
Disease and treatment factors (multi-adjusted R
2¼0.090)
b
Time since diagnosis 11.118 2.088 o0.001 10.131 2.061 o0.001
Stage at diagnosis  9.206 2.467 o0.001  6.169 2.701 0.023
Surgery (none)  10.290 3.453 0.003  8.859 3.822 0.021
Palliative Chemotherapy  5.760 2.953 0.052
Stoma  5.333 2.216 0.016  4.720 2.231 0.035
PR co-morbidities (multi-adjusted R
2¼0.027)
c
Number of PR co-morbidities  2.446 0.776 0.002  1.890 0.807 0.020
Heart disease  5.391 2.578 0.037
Anxiety/depression  6.345 3.109 0.042
Cancer (other than bowel)  8.636 2.724 0.002  6.702 2.834 0.018
Current pain
Current pain  12.469 1.943 o0.001
Hospital and GP case note reported co-morbidities (multi-adjusted R
2¼0.009)
d
Mental health  4.003 2.410 0.097
Cancer  5.620 3.063 0.067  5.620 3.063 0.067
Abbreviations: GP¼general practice; PR¼participant reported; QLQ¼quality of life questionnaire.
aFactors not significant univariately (P40.01): age, centre, education,
travelling time, employment status and smoking status.
bFactors not significant univariately (P40.01): site of cancer, recurrence, first contact (emergency versus non-emergency),
neo-adjuvant chemotherapy, adjuvant chemotherapy, neo-adjuvant radiotherapy, adjuvant radiotherapy and palliative radiotherapy.
cFactors not significant univariately (P40.01):
heart disease, high blood pressure, diabetes and osteoarthritis.
dFactors not significant univariately (P40.01): musculoskeletal, circulatory system, respiratory, gastrointestinal and
endocrine.
Number identified as
potentially eligible (n=461)
Number approached
(n=436)
Excluded (n=25)
￿  Deemed unfit by clinical team (n=24)
￿  Withdrawn for other reasons (n=1)
Number consented (n=340)
Did not consent to take part (n=96)
￿  Refused on approach by clinical team (n=88)
￿  Refused on approach by researcher (n=8)
Number recruited (n=310)
Not recruited (n=30)
￿  Ineligible (n=7)
￿  Withdrawn (e.g. failed to be recruited before end 
    of study, became unfit, etc.) (n=23)
Figure 1 Flowchart of numbers of participants approached, consented
and recruited to the study in North East Scotland.
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schemotherapy were both predictive of QoL univariately. Participants
who had not received surgery (or for whom these data were missing)
had the poorest QoL. Having a stoma was predictive of poorer QoL.
In the final disease and treatment model, shorter time since
diagnosis, metastatic (or unstaged) disease at diagnosis, no surgical
treatment and presence of a stoma remained significantly predictive
of a poorer QoL score (Table 1).
PR co-morbidities (R
2¼0.027)
Participants who reported having more than one co-morbidity had
the poorest QoL (Table 1). Of co-morbidities reported by 10% or
more of the sample, heart disease, anxiety/depression and having
another cancer (most often breast or prostate) were all signifi-
cantly associated with lower QoL scores in univariate analyses.
When modelled together, the number of PR co-morbidities and
reporting having had another cancer were significant predictors of
QoL score. Participants who reported having current pain also had
poorer QoL.
Case note recorded co-morbidities (R
2¼0.009)
These analyses were repeated for hospital and GP case note
reported co-morbidities (Table 1). None of the hospital and GP
case note reported co-morbidities were significantly associated
with QoL score, nor was the number of co-morbidities recorded.
The mental health and cancer variables were included in the final
case note model because 10% or more of the sample had the
disease and the P-value in univariate analyses was below 0.10.
Having had another cancer remained in this model (P¼0.067),
and was taken forward into the final regression model.
Function and symptoms (R
2¼0.537)
All of the QLQ-C30 functioning subscales were predictive of QoL
score, as were the symptoms of fatigue, dyspnoea, appetite loss and
diarrhoea (Table 2).
Social difficulties (R
2¼0.183)
Participants who had experienced some social difficulties (SDI
summary score) had lower QoL scores, as did those participants
who had sexual difficulties, difficulty with where they lived or
struggled with travel plans.
Cognitions (illness perceptions) (R
2¼0.198)
The IPQ-R illness identity, timeline cyclical and consequences
subscales were negatively predictive of QoL score. Thus, partici-
pants who attributed a high number of symptoms to their illness
(illness identity), who considered their illness to be cyclical and
Table 2 Associations between QLQ-C30 global quality of life score and the QLQ-C30 subscales, SDI, IPQ-R and HADS
Univariate analysis Multivariate analysis
B s.e. P-value B s.e. P-value
QLQ-C30 (adjusted R
2¼0.537)
Physical Function  13.906 1.024 o0.001  3.400 1.147 0.003
Role function  16.224 0.992 o0.001  6.586 1.225 o0.001
Emotional function  9.608 1.096 o0.001  3.141 0.912 0.001
Cognitive function  10.917 1.133 o0.001  2.170 1.009 0.032
Social function  14.447 1.090 o0.001  3.996 1.103 o0.001
Fatigue  24.558 2.189 o0.001  4.421 1.995 0.027
Nausea/vomiting  20.030 2.064 o0.001 — — —
Pain  16.131 1.823 o0.001 — — —
Dyspnoea  16.928 1.940 o0.001  3.646 1.650 0.028
Insomnia  13.073 1.877 o0.001 — — —
Appetite loss  23.089 1.882 o0.001  10.920 1.631 o0.001
Constipation  6.019 2.232 0.007 — — —
Diarrhoea  9.753 1.997 o0.001  2.835 1.441 0.050
Financial problems  9.392 2.268 o0.001 — — —
SDI (adjusted R
2¼0.183)
a
Q13 difficulty with sexual matters  7.328 2.153 0.001
Q18 difficulty with where you live  14.233 3.542 o0.001  7.532 3.592 0.037
Q20 difficulty with travel plans  13.098 1.884 o0.001  9.742 1.876 o0.001
Q21 difficulty with any other area of everyday life  13.388 2.298 o0.001
SDI summary score (dichotomous)  19.306 2.261 o0.001  15.424 2.341 o0.001
IPQ-R (tertiles) (adjusted R
2¼0.198)
IPQ illness identity  7.000 1.120 o0.001  4.029 1.131 o0.001
IPQ timeline  3.155 1.108 0.005 — — —
IPQ timeline cyclical  8.767 1.405 o0.001  4.760 1.408 0.001
IPQ consequences  9.208 1.068 o0.001  6.444 1.135 o0.001
IPQ personal control 2.869 1.213 0.018 2.297 1.178 0.052
IPQ treatment control 5.475 1.149 o0.001 2.781 1.151 0.016
IPQ illness coherence 3.257 1.094 0.003 — — —
IPQ emotional representations  8.364 1.485 o0.001 — — —
HADS (adjusted R
2¼0.271)
Anxiety  12.516 1.523 o0.001  9.779 2.314 o0.001
Depression  18.474 1.449 o0.001  24.959 2.462 o0.001
Abbreviations: HADS¼hospital anxiety and depression scale; IPQ-R¼illness perception questionnaire; QLQ¼quality of life questionnaire; SDI¼social difficulties inventory.
aSDI factors not significant univariately (P40.01): plans to have a family.
Predictors of quality of life in people with colorectal cancer
NM Gray et al
1700
British Journal of Cancer (2011) 104(11), 1697–1703 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
swho considered their illness to have negative consequences all had
poorer QoL scores. Participants who scored highly on the personal
and treatment control subscales had positive beliefs about the
controllability of the illness and their QoL scores were significantly
higher.
Anxiety and depression (R
2¼0.271)
Both the anxiety and depression subscales of the HADS were
significantly predictive of QoL score.
Final model (R
2¼0.574)
When variables from all five groupings were modelled together,
sex, number of self-reported co-morbidities, stage at diagnosis,
role and social functioning, fatigue, dyspnoea, appetite loss, HADS
depression and IPQ-R consequences were all significantly pre-
dictive of QoL score (Table 3). The fixed variables (sex,
co-morbidities and disease stage) accounted for 6.4% of the
variability in QoL score, with the remaining, modifiable variables
accounting for a further 51%.
When the QLQ-C30 functioning subscales were removed from
the model, time since diagnosis, SDI question 20 (relating to travel
plans) and the IPQ-R personal control subscale entered the model
and became significant predictors of QoL (R
2¼0.538) (Table 4).
DISCUSSION
We found that physical, psychological and social factors were all
significantly and independently associated with overall QoL. Most
predictors were modifiable, with symptoms, depression and
limitations to usual activities being most important. The only
important disease factor was having metastatic or unstaged disease
at diagnosis. The difference in QoL between those with and
without metastatic disease was around that regarded as clinically
important; differences were larger for nearly all the statistically
significant modifiable factors we identified. Women had poorer
QoL and participants’ beliefs had a role.
Table 3 Multivariate analysis of all factors from personal and social, disease and treatment, participant-reported co-morbidities, hospital and GP case
note reported co-morbidities models and questionnaire models
Including QLQ-C30 functioning scales (multi-adjusted – R
2¼0.574)
Standardised coefficients b B s.e. P-value Cumulative R
2
Fixed variables
Metastatic (or unstaged) disease at diagnosis  0.065  3.574 1.703 0.036 0.024
Number of self-reported co-morbidities  0.085  1.483 0.539 0.006 0.044
Sex  0.119  5.214 1.331 o0.001 0.064
Modifiable variables
Role function  0.267  7.255 1.078 o0.001 0.399
HADS depression   0.215  12.460 1.977 o0.001 0.477
Appetite loss  0.192  9.162 1.589 o0.001 0.530
Fatigue  0.115  6.214 1.897 0.001 0.548
Social function  0.120  3.352 1.107 0.003 0.560
Dyspnoea  0.108  4.962 1.507 0.001 0.570
IPQ-R consequences  0.085  2.158 0.866 0.013 0.574
Abbreviations: GP¼general practice; HADS¼hospital anxiety and depression scale; IPQ-R¼illness perception questionnaire; QLQ¼quality of life questionnaire.
Table 4 Multivariate analysis of all factors from personal and social, disease and treatment, participant-reported co-morbidities, hospital and GP case note
reported co-morbidities models and questionnaire models (excluding QLQ-C30 functioning scales)
Excluding QLQ-C30 functioning scales (multi-adjusted – R
2¼0.538)
Standardised coefficients b B s.e. P-value Cumulative R
2
Fixed variables
Time since diagnosis 0.107 4.993 1.623 0.002 0.073
Metastatic (or unstaged) disease at diagnosis  0.079  4.421 1.863 0.018 0.093
Number of self-reported co-morbidities  0.072  1.268 0.590 0.032 0.112
Sex  0.096  4.266 1.465 0.004 0.128
Modifiable variables
HADS depression subscale  0.266  15.440 2.174 o0.001 0.333
Appetite loss  0.237  11.458 1.749 o0.001 0.432
Fatigue  0.189  10.387 2.014 o0.001 0.485
SDI Q20 difficulty with travel plans  0.130  5.778 1.530 o0.001 0.509
IPQ-R consequences  0.112  2.874 0.955 0.003 0.520
Dyspnoea  0.096  4.450 1.697 0.009 0.530
IPQ-R personal control 0.079 2.157 0.898 0.017 0.535
HADS anxiety subscale  0.074  4.066 2.040 0.047 0.538
Abbreviations: GP¼general practice; HADS¼hospital anxiety and depression scale; IPQ-R¼illness perception questionnaire; QLQ¼quality of life questionnaire; SDI¼social
difficulties inventory.
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sThe study benefited from having as near as possible to a
consecutive sample of participants. Its age and sex distribution
reasonably approximated that of all people diagnosed with
colorectal cancer in Scotland in 2007 (http://www.isdscotland.
org/cancer). Our sample included a slightly greater proportion of
younger participants compared with that for the whole of Scotland
(9% vs 5% aged under 50 years) and slightly fewer participants
aged 80 years or more (11% vs 25%). This may reflect our
recruitment methods (via outpatient surgical and oncology clinics)
and exclusion of people whose life expectancy was o1 month or
who were unable to give informed consent (e.g., due to dementia).
We acknowledge that our findings may not fully represent those
people who were severely ill, elderly or who refused to take
part. Our questionnaire data are self-report, but we were also
able to include data from both hospital and GP case notes. Our
data were cross-sectional and, thus, cannot reflect the variation
in QoL that will inevitably occur over the cancer pathway.
However, we did collect data from patients at different stages
along the pathway, from very early diagnosis to 2 years post-
diagnosis, in an attempt to capture the differences that might
occur. The large data set we collected, including physical,
psychological and social factors, has enabled us to construct a
comprehensive picture of factors involved in QoL. A disadvantage
of having so many variables is that they may occasionally be found
to be significant by chance. However, when developing our
programme of work, we attempted to map the biological,
psychological and social mechanisms by which the QoL of people
with colorectal cancer might be affected. A priori we identified the
interactions among personal and social, NHS response, disease
state and emotional response factors as being important determi-
nants of QoL and this conceptual model was the driver for our
approach to our analysis. Our work has further clarified the way in
which these factors impact on an individual’s QoL, as illustrated in
Figure 2. It appears that the impact of personal and social, NHS
response (treatment) and disease state factors on QoL are
mediated by their impact on a person’s emotional, physical and
social functioning. This is consistent with the World Health
Organisation’s International Classification of Functioning, Dis-
ability and Health (WHO ICF) (http://www.who.int/classifications/
icf/en/), which emphasises the importance of the impact of the
disease.
Our findings on the effects of sex, stage of disease, symptoms,
beliefs about consequences and co-morbidities are in line
with a large previous Australian study despite different
instruments and settings (Steginga et al, 2009). We used the
symptom and functional domains of the EORTC-QLQ-C30 as
predictor variables (rather than outcomes) to explore how
‘body function and structure’ and ‘activity and participation’, as
classified by the WHO ICF, impacted on QoL. Thus, we confirmed
that QoL is poorer soon after diagnosis compared with later
(Arndt et al, 2006; Tsunoda et al, 2007; Wilson and Alexander,
2008) but, by exploring further, found that this difference
was accounted for by activity limitations and participation
restrictions (e.g., work, daily activities and hobbies, interference
with family and social life) as measured by EORTC-QLQ-
C30 functioning scales. These factors also partly (but not
completely) mediated the effects of symptoms on QoL.
The importance of symptoms has been reported before, but
previous studies have focussed on diarrhoea, faecal control and
constipation (Wilson et al, 2006; Steginga et al, 2009). We
found that the two most important symptoms for QoL were
fatigue and loss of appetite. In line with others (Tsunoda et al,
2007), we found that QoL was poorer for those with markers
of deprivation, including lower income and no home ownership.
That this association was not significant in our final model
suggests it is mediated by symptoms, limitations to function,
beliefs about the illness and co-morbidities. Previous studies have
also found co-morbidities to be associated with poorer QoL, but
have used either self-reported (Steginga et al, 2009) or medically
recorded (Tsunoda et al, 2007) data. By exploring both, we found
that self-reported co-morbidities are more important for QoL –
especially heart disease, anxiety/depression and having had
another cancer. We were unable to analyse less common
co-morbidities individually, but the total number of co-morbid-
ities reported was the most significant factor. We know that
not everyone who experiences symptoms of a particular disorder
(e.g., depression) seeks out medical care, so these may be
missing in case notes. Conversely, self-report may ignore diseases
that, while medically recorded, are not impacting on, or currently
active for, the person. This finding may then reflect the tendency of
people to focus on negative aspects, including those most affecting
their QoL.
If we wish to improve QoL in people with colorectal cancer, then
we need first to identify those most at risk, and second to intervene
to address factors which are modifiable (Campbell et al, 2007).
Our findings show that women, and those with metastatic (or
unstaged) disease and/or multiple co-morbidities, are affected
disproportionately and that QoL is worst in the first few months
after diagnosis and initial treatment. The variability in QoL
explained by these unmodifiable factors is, however, small and the
remaining independent predictors appear to have potential
for intervention. Symptoms and depression have strong impacts
on QoL and these can be treated. We found fatigue to be common
and particularly important; fatigue has responded in a variety
of diseases, including cancer, to programmes of graded activity
(Knols et al, 2005; Courneya and Friedenreich, 2007). Depression
and anxiety in people with cancer have improved with nurse-
led interventions, exercise and antidepressants (Strong et al, 2008).
It is also possible, with appropriate theoretically grounded
interventions, to tackle peoples’ beliefs, improving confidence
and reducing negative thoughts about consequences (Johnston
et al, 2007). Difficulties with travelling may be helped
by interventions to reduce the need for it, such as more locally
based follow up. Furthermore, if the effects of the above factors
are at least partly mediated by limitations to usual activities
(work, hobbies, etc.) and restrictions of participation in social and
family life, then it may be possible to intervene at these levels to
increase activities and participation even in the presence of the
underlying factors. There is reason, then, to be positive about the
Disease state
Tumour
properties
Co-morbidity
Symptoms
Personal and social
Sex
Affluence
Geography
Psychological response
Cognitions (illness
perceptions)
Anxiety & depression
NHS response
   Treatment
Quality of life
Functional limitations and social difficulties
Figure 2 Model of biological, psychological and social factors contributing
to QoL in colorectal cancer.
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colorectal cancer.
Our findings add to a growing literature on QoL in colorectal
cancer and show that there may be opportunities to improve it.
Our challenge now is to develop interventions, which tackle
symptoms and depression, reduce restrictions to activity and
enable people to return to as full participation as possible. While
these interventions will need rigorous evaluation, there is every
reason to be optimistic for their future.
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